A panel of three serum microRNAs as a potential diagnostic biomarker for renal cell carcinoma

一组三种血清微小RNA作为肾细胞癌的潜在诊断生物标志物

阅读:3
作者:Shengjie Lin #,Xutai Li #,Zhenjian Ge,Wenkang Chen,Yingqi Li,Pengwu Zhang,Yutong Wu,Wuping Wang,Siwei Chen,Huimei Zhou,Lingzhi Tao,Yongqing Lai

Abstract

Hitherto there is no praiseworthy noninvasive methods in the early diagnosis of renal cell carcinoma (RCC). MicroRNAs (miRNAs) could be utilized as molecular markers for diverse malignancies. In this study, we aim to discern potential miRNAs as markers for screening RCC. We employed quantitative reverse transcription-polymerase chain reaction (RT-qPCR) to detect expression levels of candidate miRNAs in serum specimens of 108 RCC patients and 112 health volunteers. Diagnostic values of miRNAs were appraised, and panel was constructed by dint of receiver operating characteristic curves, the area under the ROC curve and backward stepwise logistic regression analysis. Moreover, we capitalized on bioinformatics analysis for exploration of miRNAs biological functions. The expression of five miRNAs (miR-30c-5p, miR-142-3p, miR-206, miR-223-3p, miR-200c-5p) were markedly alteration in serum specimens of RCC patients and health subjects. A three-miRNA panel combining miR-30c-5p, miR-142-3p and miR-206 was constructed and could discriminate RCC patients and healthy subjects satisfactorily with 0.872 (0.811-0.919, P < 0.001) AUC, 81.25% sensitivity and 86.90% specificity. ATF3 and MYC seem to be potential targets of the three-miRNA panel. The novel miRNA-based panel may perform as potential noninvasive markers to discriminate RCC patients and healthy subjects in advance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。